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Introduction
The emergence of  the mineralocorticoid aldosterone supposedly promoted the evolution of  terrestrial ver-
tebrates (1). Aldosterone facilitates adaptation to land life by conserving salt and water in the intestine and 
kidney and facilitating renal acid elimination. Acid-base balance is crucial for all enzyme-based reactions. 
When metabolic rate and, hence, acid production increases, efficient acid elimination becomes essential, 
which in homeothermic mammals relies on lungs and kidneys. Aldosterone enhances renal acid elimina-
tion in the form of  ammonium and through urinary acidification (2). Aldosterone deficiency therefore 
impairs renal acid excretion, and the ensuing metabolic acidosis elicits respiratory compensation.
Inappropriately high aldosterone levels, however, contribute to the development and progression of  
cardiovascular and renal diseases (3) and predispose for hypertension, diabetes, and hyperlipidemia (4). 
Consistent with its pathophysiological role, inhibiting aldosterone action with mineralocorticoid receptor 
(MR) antagonists or by blocking the renin-angiotensin system with angiotensin-converting enzyme inhibi-
tors (ACEIs) or angiotensin-II receptor blockers (ARBs) slows kidney disease progression (5, 6). They also 
reduce cardiovascular mortality and improve health-related quality of  life in heart failure patients (7, 8). 
However, aldosterone breakthrough, i.e., the return of  aldosterone levels to or above pretreatment values, 
commonly reduces the efficacy of  ACEIs and ARBs with chronic use (9). In addition, these medications do 
Aldosterone synthase inhibitors (ASIs) should alleviate obesity-related cardiovascular and renal 
problems resulting partly from aldosterone excess, but their clinical use may have limitations. 
To improve knowledge for the use of ASIs, we investigated physiology in aldosterone synthase–
knockout (ASKO) mice. On regular chow diet (CD), ASKO mice ate more and weighed less than WT 
mice, largely because they hyperventilated to eliminate acid as CO2. Replacing CD with high-fat 
diet (HFD) lessened the respiratory burden in ASKO mice, as did 12- to 15-hour fasting. The latter 
eliminated the genotype differences in respiratory workload and energy expenditure (EE). Thus, 
aldosterone deficiency burdened the organism more when the animals ate carbohydrate-rich chow 
than when they ate a HFD. Chronic HFD exposure further promoted hyperinsulinemia in ASKO 
mice that contributed to visceral fat accumulation accompanied by reduced lipolysis, thermogenic 
reprogramming, and the absence of weight-gain-related EE increases. Intracerebroventricular 
aldosterone supplementation in ASKO mice attenuated the HFD-induced hyperinsulinemia, but did 
not affect EE, suggesting that the presence of aldosterone increased the body’s energetic efficiency, 
thus counteracting the EE-increasing effect of low insulin. ASIs may therefore cause acid-overload-
induced respiratory burden and promote obesity. Their use in patients with preexisting renal and 
cardiopulmonary diseases might be contraindicated.
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not protect against MR-independent actions of  aldosterone on organ damage, such as aldosterone-induced 
pancreatic β cell loss (10). These issues prompted the development of  several potent aldosterone synthase 
inhibitors (ASIs) (11–14). Currently available ASIs improve some metabolic health parameters in preclin-
ical models and clinical trials (14–16), but may not exclusively have beneficial effects. To improve basic 
knowledge for the safe use of  ASIs, we used here the well-characterized aldosterone synthase–knockout 
(ASKO) mice (17) to investigate how low aldosterone levels affect physiology. As obesity is linked to hyper-
aldosteronism and a high risk of  cardiovascular mortality (18), obese individuals supposedly benefit from 
ASI therapy. We therefore performed the experiments not only in mice fed regular chow diet (CD) but also 
in diet-induced obese (DIO) mice chronically fed a high-fat diet (HFD).
Results
ASKO mice fed CD and maintained at 22°C overeat without increasing BW. CD-fed 2.5-month-old ASKO mice 
weighed less than WT controls (ASKO vs. WT: male, 23.1 ± 1.4 vs. 28.7 ± 1.7 g; female, 18.3 ± 1.3 vs. 
22.5 ± 2.0 g) (Figure 1, A–C). Body composition, i.e., the weights of  individual fat depots as well as the 
weights of  brain, heart, kidney, spleen, and thymus were similar in ASKO and WT mice after normaliza-
tion to BW (Figure 1D, and see below). Therefore, aldosterone deficiency restricts growth symmetrically 
and does not selectively affect the growth of  soft tissue and organs or fat distribution. As reported pre-
viously (19), 5-month-old ASKO mice on CD were hyperkalemic, polyuric, and polydipsic with a lower 
BP compared with WT mice (Table 1 and Supplemental Figure 1; supplemental material available online 
with this article; https://doi.org/10.1172/jci.insight.99015DS1). Their tail arterial blood contained lower 
levels of  bicarbonate (Supplemental Figure 2A) than those of  WT mice and appeared slightly more acidic 
(ASKO, pH 7.31 ± 0.01; WT, pH 7.34 ± 0.02). Both genotypes had similar venous lactate levels (Supple-
mental Figure 2C).
ASKO mice ate more than WT mice relative to BW at 22°C (Figure 1E), despite aldosterone-deficien-
cy-related metabolic acidosis (19), which in humans commonly reduces appetite (20). Their greater food 
intake is not a compensatory response to the reduced body Na+ content. In both CD-fed and HFD-fed 
ASKO mice, salt supplementation (1% NaCl drinking water; Supplemental Figure 3, G and P) increased 
— rather than decreased — food intake along with water intake (Supplemental Figure 3, A, C, J, and L). 
Moreover, the absolute amount of  food consumed ad libitum was similar in both genotypes, as were the 
1.5- and 3.5-hour intakes after 15-hour fasting (Figure 1, E and F). This suggests that aldosterone defi-
ciency did not compromise the ability to adjust food intake in response to a change in body energy status. 
We then suspected a reduced intestinal uptake of  short-chain fatty acids (SCFAs) in ASKO mice. SCFAs 
can provide 20%–30% of  daily caloric requirements of  omnivores, including mice (21). As aldosterone 
stimulates colonic Na+ absorption (22) and increases enterocyte membrane fluidity (23), thus facilitating 
passive SCFA diffusion, aldosterone deficiency might impair Na+-coupled and -uncoupled SCFA transport 
in the large intestine (24). Surprisingly, ASKO mice lost less propionic and butyric acid in feces than WT 
mice (Figure 1G). Even after normalization to cecal SCFA contents, fecal SCFA levels in ASKO mice were 
still not higher than those in WT mice (Figure 1H). Daily fecal energy loss also did not differ between 
genotypes (Figure 1I). In sum, ASKO mice retain the capacity to regulate energy homeostasis in response 
to changes in body energy status. The increased food intake in ASKO mice is therefore unlikely an uncon-
trolled overeating resulting from aldosterone deficiency nor is it related to a reduced total body Na+ content 
or to a reduced intestinal SCFA or nutrient absorption. The conversion of  excess energy into fat was not 
affected by aldosterone deficiency either because in the nonfasting state plasma triglyceride (TG) and glu-
cose levels were comparable in ASKO and WT mice, as was plasma insulin (Table 2).
Thermoneutral housing and fasting counteract the hyperventilation and increased energy expenditure of  ASKO mice 
fed CD at 22°C. Food and fluid intake influence each other. The greater water intake in ASKO mice might 
therefore be related to overeating. Unsurprisingly, 16-hour water restriction drastically inhibited eating in both 
genotypes (Supplemental Figure 3, C and L). ASKO mice had a greater urinary Na+ excretion/Na+ intake ratio 
than WT mice (Supplemental Figure 3, I and R), indicating they had a greater reduction in circulating volume. 
During water restriction, ASKO mice ate similar amounts of food and produced similar amounts of feces and 
urine as WT mice, but lost more weight (Supplemental Figure 3, A–E and J–N). This suggested greater energy 
expenditure (EE) in ASKO than in WT mice. Indirect calorimetry confirmed that ASKO mice maintained at 
22°C had higher EE than WT mice, especially during the dark (active) and early light phase (Figure 2A) despite 
being as physically active as WT mice (Supplemental Figure 4C). ASKO mice were, however, hyperventilating, 
3insight.jci.org   https://doi.org/10.1172/jci.insight.99015
R E S E A R C H  A R T I C L E
as implied by a respiratory exchange ratio (RER) above 1 (Figure 2B) and by a trend toward a reduced pCO2 
level in the tail arterial blood compared with WT mice (Supplemental Figure 2A). Their hyperventilation is 
presumably a compensation for reduced renal capacity to eliminate acids that results in less arterial bicarbonate 
to buffer acids compared with WT mice (Supplemental Figure 2A).
Hyperventilation is energetically costly; in humans the energy cost of  breathing increases exponen-
tially with enhanced ventilation (25). In the mid-dark phase, ASKO compared with WT mice displayed 
increases in both respiratory rate (RR) and minute volume (MV) (Figure 2, C and E), and had a short-
ened breathing cycle with a reduced expiratory time and a trend toward a reduced inspiratory time 
(Supplemental Figure 4, D and E). The high EE of  ASKO mice may therefore be due to the extra work 
of  breathing. Consistent with this possibility, the EE difference between the dark and light phases was 
greater in ASKO mice than in WT mice (Figure 2A). To further examine the role of  hyperventilation 
in the high EE in CD-fed ASKO mice maintained at 22°C, we alleviated their respiratory workload 
by 12–15 hours of  fasting at 22°C or by increasing the housing temperature to thermoneutrality. Fast-
ing prompts cells to switch from burning carbohydrates to burning fat for fuel. Fat oxidation results 
Figure 1. Chow diet–fed (CD-fed) ASKO mice at 22°C maintained BW at a lower level but ate more than WT mice, which was not related to decreased 
intestinal nutrient absorption. (A) BW tracked from 2.5 months of age (n = 4/group, mean ± SD). (B) Adult WT and ASKO mice maintained on CD. 
(C) BW of 2.5-month-old female mice (n = 4/group, mean ± SD). (D) Box-and-whisker plot for relative organ size (organ mass/BW), small and large 
intestine length (organ length/BW0.5) of 2.5-month-old female mice (n = 4/group). Box = median + interquartile range, whisker = 10%–90% of distribu-
tion. WT mean set to 100. (E) Daily food intake of 6-month-old mice (n = 4/group, mean ± SD). (F) 1.5- and 3.5-hour food intake after 15-hour fasting 
of 2.5-month-old mice (n = 5–7/group, mean ± SEM). (G–I) Daily fecal short-chain fatty acid (SCFA) loss (G), cecal SCFA contents (left) and the ratio 
of fecal to cecal SCFA contents (right) (H), and fecal energy loss of 6-month-old mice (I) (n = 5–7/group, mean ± SEM). *P < 0.05 WT versus ASKO by 
Mann-Whitney U test (A, C, and E) or by Welch’s unpaired t test (F–I).
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in less CO2 production than carbohydrate 
oxidation for generating the same amount of  
ATP (26). It also reduces whole-body energy 
needs, which decreases CO2 production. Less 
CO2 production could alleviate the respiratory 
burden. Accordingly, fasting reduced RR, MV, 
and EE in both genotypes (Figure 2, C, E, and 
F). It reduced MV and tidal volume more in 
ASKO than in WT mice (Figure 2, D and E) 
and eliminated the EE difference between gen-
otypes (Figure 2F). These results suggest that 
at 22°C metabolizing carbohydrates imposes 
an energetic burden on the respiratory system 
and physiology of  ASKO mice, which is alle-
viated by the prolonged fasting that enhances 
metabolizing fat.
The 22°C housing temperature represents 
a mild cold stress for mice. That increases 
EE, body acid load, and hence ventilation by 
increasing metabolic rate (CO2 production) 
(27) and activating brown adipose tissue (BAT). 
Accordingly, raising the housing temperature to 30°C (thermoneutrality) reduced O2 consumption and 
CO2 production and EE in both genotypes (Figure 2A and Supplemental Figure 4, A and B). The average 
RER of  ASKO mice during the late 80% dark phase, however, was only mildly reduced, though never 
exceeded 1 throughout the light phase (Figure 2B), suggesting that ASKO mice still substantially relied 
on respiration to maintain acid-base balance at 30°C. Such partial relief  — as opposed to complete relief  
— of  respiratory burden of  ASKO mice by thermoneutral housing might explain why reductions in EE 
in ASKO mice were not significantly larger than those in WT mice in both dark and light phases (Figure 
2A). Nonetheless, thermoneutral housing was sufficient to eliminate the genotype differences in EE, O2 
consumption, CO2 production, and food intake observed at 22°C (Figure 2A and Supplemental Figure 4, 
A, B, and F). Collectively, these data indicate that the genotype differences in EE and food intake at 22°C 
and on carbohydrate-rich CD are mainly due to hyperventilation in ASKO mice. The greater food intake 
in ASKO mice at 22°C is therefore likely a compensation for their higher EE, although it also contributes 
to the increased EE as would any physical activity.
ASKO mice are particularly prone to HFD-induced visceral adiposity and hyperinsulinemia. Fasting ASKO 
mice to lower body energy needs and to enhance fat utilization reduced the respiratory burden and EE 
to the levels of  WT mice even under mild cold stress of  22°C. We therefore studied how long-term HFD 
feeding affects energy balance in ASKO mice. We switched ASKO mice fed CD until the age of  2.5 months 
to HFD. After several weeks on HFD, ASKO mice gained more weight than WT. After 14 weeks on HFD, 
ASKO mice weighed more than WT mice (42.7 ± 1.7 vs. 37.6 ± 1.4 g) and had more body fat (Figure 3, 
A–D), with no change in BP (Supplemental Figure 1). Perirenal, mesenteric, and BAT depots were enlarged 
(Figure 3E), and mesenteric adipocytes were larger in ASKO mice than in WT mice (7,075 ± 194.6 and 
4,929 ± 166.2 μm2, respectively [mean ± SEM]) (Figure 3, F and G). mRNA analysis of  Pparg and Cebpa, 
master regulators of  adipogenesis, revealed no genotype differences (Figure 3H). Collectively, these data 
indicate that aldosterone deficiency predisposes mice to HFD-induced visceral adiposity by enhancing adi-
pocyte hypertrophy. Consistent with the morphological difference, ASKO mice had higher plasma insulin 
than WT mice after 14 weeks on the HFD (Table 2).
ASKO mice visceral adipose tissue shows reduced thermogenic reprogramming and lipolysis in response to chronic 
HFD feeding. Chronic HFD feeding produces diet-induced thermogenesis (DIT) in rodents. DIT partially 
manifests as an activation of  the thermogenic program in BAT and white adipose tissue (WAT) (28). Anal-
ysis of  BAT and perirenal WAT of  14-week HFD-fed mice by RT2 profiler PCR array (Qiagen), focusing 
on adipose metabolism, revealed no differences between BAT of  ASKO and WT mice. Perirenal WAT of  
ASKO mice, however, tended to have decreased expression of  thermogenesis-related genes (Supplemental 
Figure 5A and Supplemental Table 4). Subsequent qRT-PCR revealed that chronic HFD feeding caused a 
Table 1. Water intake, urine osmolality, and urine and plasma electrolyte profiles of 
CD-fed WT and ASKO mice
CD
WT ASKO
Water intake (ml/20 g BW /24 h) 2.82 ± 0.20 3.66 ± 0.57A
Urine:  
Volume (ml/20 g BW/24 h) 0.48 ± 0.06 1.15 ± 0.11A
Daily Na+ excretion (μmol/24 h) 130.66 ± 24.4 195.23 ± 21.28A
Urinary Na+ excretion/Na+ intake (24 h) 0.42 ± 0.11 0.59 ± 0.03
Daily K+ excretion (μmol/24 h) 447.29 ± 71.26 547.85 ± 72.82
Urinary K+ excretion/K+ intake (24 h) 0.62 ± 0.13 0.71 ± 0.07
Creatinine clearance rate (ml/min) 0.24 ± 0.06 0.32 ± 0.04
Osmolarity (mOsm/kg H2O) 3,835 ± 1,074 1,780 ± 289
A
Plasma:
Na+ (mEq/l) 155.25 ± 3.57 156.05 ± 3.89
K+ (mEq/l) 4.14 ± 0.24 5.14 ± 0.49A
All values displayed as mean ± SD. n = 4/group. AP < 0.05 WT versus ASKO by Mann-Whitney 
U test.
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2- to 3-fold increase in the expression of  core thermogenic genes, including uncoupling protein-1 (Ucp1), 
peroxisome proliferator-activated receptor α (Ppara), peroxisome proliferator-activated receptor γ coact-
ivator-1 α (Pgc1a), and peroxisome proliferator-activated receptor γ coactivator-1 β (Pgc1b), in perirenal 
WAT of  WT mice (Figure 4A). This response was absent in ASKO mice (Figure 4A). Accordingly, their 
downstream targets, such as fatty acid oxidation enzymes and transcription factor-A, mitochondria (Tfam), 
nuclear respiratory factor-1 (Nrf1), and nuclear respiratory factor-2 (Nrf2) — principal transcription factors 
governing mitochondrial biogenesis — were expressed at reduced levels in the perirenal WAT of  ASKO 
mice (Figure 4, B and C). Despite these changes, ASKO mice retain similar levels of  mitochondrial mass 
and mitochondrial aerobic capacity to those of  WT mice, as citrate synthase activity assay of  perirenal fat 
(a surrogate of  these 2 mitochondrial parameters) (29, 30) did not reveal genotype differences (Figure 4D). 
The absence of  thermogenic reprogramming in perirenal fat of  ASKO mice was paralleled by reduced 
lipolysis in their visceral adipose tissue (VAT). Compared with WT mice, ASKO mice expressed lower 
amounts of  the active, phosphorylated form of  hormone-sensitive lipase (HSL) in perirenal fat (P = 0.11) 
and mesenteric fat (Supplemental Figure 5D and Figure 4E). They also had reduced plasma nonesterified 
fatty acid (NEFA) levels and tended to have decreased liver TG content (Figure 4, F–H).
Thermogenic reprogramming and lipolysis in DIT are sympathetically stimulated with norepineph-
rine-activating β3-adrenergic receptor (β3-AR). Assessing tyrosine hydroxylase (TH), an indirect measure 
of  sympathetic innervation (31), by immunofluorescence and immunoblotting revealed similar TH levels 
in VAT of  both genotypes (Supplemental Figure 5, E and F). β3-AR (Adrb3) in perirenal fat tended to be 
reduced only at the mRNA and not at the protein level (Supplemental Figure 5, G and H). These data 
suggest that the impaired lipolytic and thermogenic response of  VAT, which makes HFD-fed ASKO mice 
more prone to developing central obesity, is unrelated to a reduced sympathetic input.
Switching from CD to HFD feeding reduces the respiratory burden in ASKO mice. To elucidate the mecha-
nisms underlying the increased susceptibility of  ASKO mice to HFD-induced obesity at 22°C, we focused 
on their changes in EE and food intake over time because aldosterone deficiency did not alter intestinal 
nutrient absorption (Figure 1I). After 10 weeks of  HFD, the energy intake of  both genotypes was reduced 
compared with 5-week HFD feeding (Figure 5D). Compared with CD consumption, HFD consumption 
increases the utilization of  fat for fuel and, hence, decreases the production of  CO2, which is the main 
stimulator of  breathing. We therefore assumed that the switch to HFD would enhance metabolic efficien-
cy in ASKO mice more than in WT mice because ASKO mice might then not have to hyperventilate much 
to achieve acid-base balance. Consistent with this assumption, 5-week HFD-fed ASKO mice eliminated 
less CO2 in the dark phase than those maintained on CD (Figure 5C). Also, while ASKO mice had greater 
CD-refeeding-induced increases in EE (35.10% ± 5.50% in ASKO vs. 21.95% ± 1.90% in WT mice), RR, 
Table 2. Plasma lipid profile and glucose and insulin levels in WT and ASKO mice maintained on CD or on HFD
CD HFD
WT ASKO WT ASKO
Metabolites and hormones
Nonfasted Glucose (mg/dl) 168.7 ± 12.7 198.3 ± 26.1 195.4 ± 34.4 170.8 ± 33.9
Triglycerides (mg/dl) 126.3 ± 4.0 123.0 ± 29.4 190.8 ± 44.6 126.0 ± 53.7A
Free fatty acids (mM) 0.53 ± 0.17 0.48 ± 0.07 shown in Figure 4H
Cholesterol (mg/dl) 95.8 ± 13.2 129.8 ± 29.8 157.2 ± 36.5 148.0 ± 30.3
Insulin (ng/ml) 0.33 ± 0.15 0.39 ± 0.1 1.15 ± 0.4 5.07 ± 1.5B
Aldosterone (pg/ml) 350.54 ± 88.66 21.3 ± 4.41C 332.60 ± 58.67 32.36 ± 18.64B
Corticosterone (nM) - - 408.7 ± 97.4 289.6 ± 51.7
11-Dehydrocorticosterone (nM) - - 2.6 ± 1.1 3.6 ± 0.7
Fasted Glucose (mg/dl) - - 161.2 ± 44.7 138.7 ± 29.5
Triglycerides (mg/dl) - - 123.8 ± 16.2 72.1 ± 12.8A
Insulin (ng/ml) - - 0.29 ± 0.08 0.25 ± 0.05
All values displayed except insulin and aldosterone as mean ± SD, n = 4–5/group in nonfasted condition, n = 3/group in fasted condition. Values for insulin 
in both nonfasted and fasted condition and for aldosterone displayed as mean ± SEM, n = 3–7 /group. AP < 0.05; BP < 0.01; CP < 0.001; HFD-fed WT versus 
HFD-fed ASKO or CD-fed WT versus CD-fed ASKO; Welch’s unpaired t test.
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and MV than WT mice, they increased EE by only 20% in response to HFD refeeding, similar to WT 
mice (Figure 5E and Supplemental Figure 6A). WT and ASKO mice consumed similar amounts of  food 
during the refeeding period of  CD or of  HFD (Supplemental Figure 6B). Refeeding ASKO mice with 
HFD increased respiratory workload less than refeeding them with CD. This clear differential response 
in EE and respiratory workload to different diets was absent in WT mice. This suggests that HFD feeding 
increased the susceptibility of  ASKO mice to HFD-induced obesity by relieving the respiratory burden 
more than in WT mice.
Chronic HFD feeding increases EE (32, 33) through DIT and weight-gain-induced increases in cellular 
energy demand because some cells increase substantially in number (e.g., hematopoietic cells) (34–36) and some 
in both number and size (e.g., adipocytes). Cells obtain energy primarily by oxidizing nutrients, which gener-
ates CO2. Accordingly, WT mice steadily increased EE, O2 consumption, and CO2 elimination with increasing 
weight (Figure 5, A–C). After 5 weeks on the HFD, EE of WT mice tended to be higher (7%) than on CD, 
Figure 2. Chow diet–fed (CD-fed) ASKO mice at 22°C were hyperventilating and had greater energy expenditure (EE) than WT mice in the dark and early 
light phase. Twelve to 15 hours of fasting eliminated and thermoneutral housing alleviated these changes. (A) Temporal changes in EE of 4-month-old mice 
at 22°C and 30°C. Calculated changes in EE between dark and light phase at 22°C and between 22°C and 30°C housing of both genotypes (n = 5–7/group, 
mean ± SEM). (B) Temporal changes in respiratory exchange ratio of 4-month-old mice at 22°C and 30°C (n = 5–7/group, mean ± SEM). (C–E) Respiratory rate 
(RR) (C), tidal volume (TV) (D), and minute volume (MV) (E) of 3-month-old ad libitum–fed mice and after 12–15 hours of fasting at 22°C and the calculated 
changes for each respiratory parameter between fasted and ad libitum fed (n = 5–8/group, mean ± SEM). (F) Temporal changes in EE of 3-month-old mice at 
22°C after food (CD) deprivation from the mid-light phase (n = 5–7/group, mean ± SEM). *P < 0.05 WT versus ASKO by Welch’s unpaired t test.
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and after 5 more weeks this difference was significant (Figure 5A). Chronic HFD feeding also increased O2 
consumption in both dark and light phases (10 weeks compared with 5 weeks, Figure 5B), and CO2 elimination 
appeared to be also increased, although the difference reached significance only in the light phase (Figure 5C). 
On the other hand, in ASKO mice chronic HFD feeding did not increase EE, and the genotype difference in EE 
observed at 22°C in mice fed the CD disappeared after 10 weeks on HFD (Figure 5A). O2 consumption and CO2 
elimination in ASKO mice remained unchanged between 5 and 10 weeks of HFD feeding, although the animals 
became obese and had an activated thermogenic program in BAT (Supplemental Figure 7). Collectively, these 
results suggest that weight-gain-associated increases in EE were masked in HFD-fed ASKO mice. Though HFD 
feeding improves energetic efficiency in ASKO mice by alleviating the respiratory burden, this effect should have 
started early on after the switch from CD to HFD. We then proceeded to study whether chronic HFD feeding–
induced hyperinsulinemia could influence adiposity progression in ASKO mice by affecting EE.
Figure 3. ASKO mice were more prone to high-fat diet–induced (HFD-induced) visceral adiposity. (A and B) BW and BW changes tracked from the age 
of 9 weeks (n = 7–8/group, mean ± SEM). *P < 0.05, **P < 0.01 HFD-fed WT versus HFD-fed ASKO by Welch’s unpaired t test. (C) WT and ASKO mice 
maintained on HFD for 12 weeks. (D and E) Body composition (D) and (E) weights of inguinal (ing.), epididymal (e.), perirenal (pr.) and mesenteric (mes.) 
white adipose tissue (WAT), and interscapular brown adipose tissue (BAT) after normalization to BW in mice fed chow diet (CD) and HFD (n = 4–8/group, 
mean ± SEM). #P < 0.05, ##P < 0.01 by 1-way ANOVA followed by Tukey’s post hoc test. (F and G) Representative histological sections of H&E-stained 
mesenteric fat of HFD-fed mice (F). Scale bars: 100 μm. (G) Box-and-whisker plot and distribution of adipocyte sizes of mesenteric fat (n = 3 [WT], n = 4 
[ASKO], 50–100 adipocytes/mouse). ***P < 0.001 for mean adipocyte size difference between HFD-fed WT and ASKO mice by Welch’s unpaired t test. Box 
= median + interquartile range, whisker = 10%–90% of distribution. (H) Pparg and Cebpa mRNA levels in perirenal fat (n = 3/group, mean ± SD). Welch’s 
unpaired t test. Data in D–H were obtained from 2.5-month-old mice fed CD or HFD for another 14 weeks.
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Chronic hyperinsulinemia contributes to the increased obesity in ASKO mice fed the HFD. Chronic HFD feed-
ing increased adiposity and plasma insulin levels more in ASKO mice than in WT mice (Table 2). Hyper-
insulinemia can be an accelerator of  diet-induced obesity (37, 38) or an accompanying change resulting 
from the adiposity-dependent progression of  insulin resistance (39). We therefore tracked plasma insulin 
in HFD-fed ASKO and WT mice over time. After only 1 week on the HFD, ASKO mice tended to have 
higher insulin levels than WT mice (Supplemental Figure 8C), and the difference reached significance by 8 
weeks, when the percentage of  fat in both genotypes was the same (Figure 6, A and B). This suggests that 
the higher insulin levels in ASKO mice are unlikely adiposity dependent. We further asked whether low-
ering the insulin levels of  14-week HFD-fed ASKO mice by overnight fasting (16 hours) would reactivate 
the suppressed lipolysis and transcriptional expression of  thermogenic genes. As DIT does not cease with 
overnight fasting (40), there should still be a continuous sympathetic input to VAT under these conditions.
Figure 4. Visceral adipose tissue (VAT) of ASKO mice was unresponsive to 14-week high-fat diet (HFD) feeding–induced activation of the thermogenic 
program and lipolysis. (A) mRNA levels of thermogenic genes of perirenal fat of chow diet (CD) and HFD-fed WT and ASKO mice (n = 3–4/group, mean ± 
SD). #P < 0.05, ##P < 0.01, ###P < 0.001 by 1-way ANOVA followed by Tukey’s post hoc test. (B and C) mRNA levels of enzymes involved in fatty acid oxi-
dation (B) and in mitochondrial DNA transcription and replication in perirenal fat (C) of HFD-fed mice (n = 3–4/group, mean ± SD). *P < 0.05 HFD-fed WT 
versus HFD-fed ASKO by Welch’s unpaired t test. MCAD, medium-chain acyl-Coenzmye A dehydrogenase; EHHAD, enoyl-Coenzyme A hydratase; HADH, 
hydroxyacyl-Coenzyme A dehydrogenase; ACAA1b, acetyl-Coenzyme A acyltransferase 1b. (D) Citrate synthase activity in perirenal fat of 12- to 14-week 
HFD-fed mice (n = 6/group, mean ± SEM). Welch’s unpaired t test. (E) Western blot analysis of p-HSL, HSL, ATGL, and actin in mesenteric fat of HFD-fed 
WT and ASKO mice. Results presented after normalization to corresponding HSL and actin (n = 3/group, mean ± SD). *P < 0.05 HFD-fed WT versus HFD-
fed ASKO by Welch’s unpaired t test. HSL, hormone-sensitive lipase; ATGL, adipocyte triglyceride lipase. (F) Representative sections of H&E-stained livers 
of HFD-fed WT and ASKO mice (n = 4/group). Scale bars: 100 μm. (G and H) Liver triglyceride (TG) contents (G) and plasma nonesterified fatty acid (NEFA) 
levels (H) of HFD-fed WT and ASKO mice (n = 3–4/group, mean ± SD). *P < 0.05 HFD-fed WT versus HFD-fed ASKO by Welch’s unpaired t test.
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Overnight fasting reduced plasma insulin of  WT and ASKO mice to a similar level (Table 2) 
and provoked VAT lipolysis in both genotypes similarly, as evidenced by their quantitatively similar 
increases in liver TG (Figure 6C). Consistent with reactivation of  lipolysis, VAT of  fasted ASKO mice 
showed an activation of  the intracellular lipolytic cascade with p-HSL/HSL similar to that of  WT 
mice and an even higher protein level of  adipocyte triglyceride lipase (ATGL) (Figure 6E). Fasting 
also increased thermogenic gene transcripts similarly in WT and ASKO mice (Figure 6D). On the 
other hand, the homeostatic model assessment of  insulin resistance suggested a similar degree of  
insulin resistance in WT and ASKO mice (Figure 6F). Collectively, these results suggest that the 
hyperinsulinemia is a cause rather than an effect of  the increased susceptibility of  ASKO mice to 
HFD-induced obesity.
Figure 5. Switching from chow diet (CD) to high-fat diet (HFD) feeding reduced the respiratory burden in ASKO mice. Unlike in WT mice, chronic HFD 
feeding did not increase energy expenditure (EE) in ASKO mice. (A–C) AUC of (A) EE (B) O2 consumption (C) CO2 production of CD-fed (5 weeks) and HFD-
fed (5 and 10 weeks) WT and ASKO mice (n = 5–7/group, mean ± SEM). *P < 0.05, CD-fed ASKO versus CD-fed WT or 5-week HFD-fed ASKO versus 5-week 
HFD-fed WT. #P < 0.05, 10-week HFD-fed WT versus CD-fed WT. ##P < 0.01, 10-week HFD-fed WT versus 5 week HFD-fed WT. †P < 0.05, CD-fed ASKO 
versus 5-week HFD-fed ASKO. (D) Daily energy intake (n = 6–12/group, mean ± SEM). **P < 0.01 CD-fed ASKO versus CD-fed WT or 5-week HFD-fed ASKO 
versus 5-week HFD-fed WT. (E) Changes in EE in response to refeeding of CD or HFD for 3.5 hours in 15-hour fasted, 3-month-old mice. Changes in EE = 
AUC EE following diet for 3.5 hours – AUC EE before diet for 3.5 hours. Fasting-refeeding was performed in the same mice, first with CD and 4 days later 
with HFD (n = 5–7/group, mean ± SEM). All data analyzed by Welch’s unpaired t test. In A–C, data of CD-fed (5 weeks) mice are also shown in Figure 2A and 
Supplemental Figure 4, A and B.
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I.c.v. infusion of  aldosterone reduces plasma insulin and tends to attenuate weight gain in ASKO mice fed the 
HFD. HFD-induced hyperinsulinemia was lower in WT than in ASKO mice, but lack of  endogenous 
peripheral aldosterone did not increase plasma insulin levels in CD-fed ASKO mice (Table 2). HFD feed-
ing did not increase plasma aldosterone levels in WT mice (Table 2), suggesting that the central lack of  
aldosterone might be more important than peripheral aldosterone deficiency for regulating HFD-induced 
hyperinsulinemia. Adrenal-derived aldosterone appears to determine brain aldosterone levels (41). Chronic 
HFD feeding may have increased brain aldosterone in WT mice because it compromises the blood-brain 
barrier (42), potentially increasing the entry of  aldosterone into the brain as occurs similarly for peripheral 
cholesterol (43). Because EE-reducing effects of  hyperinsulinemia appear to be powerful enough to mask 
weight-gain-induced EE increases, whereas aldosterone deficiency causes an increase in energy turnover by 
respiration that is smaller with HFD than with CD feeding, aldosterone supplementation directly into the 
brain of  HFD-fed ASKO mice may attenuate their hyperinsulinemia and weight gain.
Ten- to 12-week HFD-fed ASKO mice were i.c.v. infused for 4 weeks at 25 ng/h with aldosterone 
dissolved in artificial cerebrospinal fluid (aCSF). I.c.v. aldosterone did not increase plasma aldosterone 
levels in WT mice, possibly because it suppressed endogenous aldosterone production after drainage 
Figure 6. Visceral adipose tissue (VAT) of 14-week HFD-fed ASKO mice responded to 16-hour fasting–induced lipolysis and thermogenic gene activation. (A 
and B) Plasma insulin levels (blood collected from tail in the dark phase) (A) and body composition (B) of mice fed HFD for 8 weeks (n = 6/group, mean ± SEM). 
(C) Liver triglyceride (TG) levels of HFD-fed WT and ASKO mice in nonfasted and fasted states (n = 3–4/group, mean ± SD). (D) mRNA levels of thermogenic 
genes of perirenal fat of HFD-fed WT and ASKO mice (n = 3–4/group, mean ± SD). (E) Western blot analysis of p-HSL, HSL, ATGL, and actin in mesenteric fat 
of fasted HFD-fed WT and ASKO mice. Results presented as relative protein levels of p-HSL and ATGL after normalization to corresponding HSL and actin (n 
= 3/group, mean ± SD). (F) Insulin resistance determined using homeostatic model assessment (HOMA-IR) index. HOMA-IR was calculated by multiplying 
16-hour fasting insulin (μU/ml) with 16-hour fasting glucose (mmol/l) and dividing by 22.5 (n = 3/group, mean ± SD). *P < 0.05, **P < 0.01, HFD-fed ASKO 
versus HFD-fed WT by Welch’s unpaired t test (A, B, E, and F). In C and D, data of ad libitum HFD-fed mice are also shown in Figure 4, A and G.
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into systemic circulation from cranial sinuses, but did raise plasma aldosterone levels of  ASKO mice to 
almost two-thirds of  those in WT mice (Figure 7B). I.c.v. aldosterone appeared to increase food intake 
in WT mice, likely because aldosterone can stimulate appetite (44). I.c.v. aldosterone tended to reduce 
weight gain and food intake and attenuated hyperinsulinemia in HFD-fed ASKO mice (Figure 7, A, C 
and D). As in WT mice, i.c.v. aldosterone did not increase EE, O2 consumption, or CO2 production in 
ASKO mice (Figure 7, E–G), suggesting the reducing effects of  aldosterone on EE through alleviating 
respiratory burden balanced the increasing effect of  the reduced insulin level. Surprisingly, chronic aCSF 
infusion alone eliminated the difference in the level of  pHSL/HSL between HFD-fed WT and ASKO 
mice. I.c.v. aldosterone decreased ATGL in HFD-fed ASKO mice, but had no effect in HFD-fed WT 
mice (Figure 7H). Collectively, these results indicate that aldosterone has a suppressive effect on diet- 
induced hyperinsulinemia. The unchanged EE and gas exchange rates after i.c.v. aldosterone infusion in 
HFD-fed ASKO mice suggest that the attenuation of  HFD-induced weight gain by i.c.v. aldosterone in 
ASKO mice is likely mediated by the reduction in food intake.
Discussion
Aldosterone facilitated the evolution of  terrestrial vertebrates by enabling Na+ and water conservation as 
well as renal acid excretion. Consistent with aldosterone’s key role in electrolyte, hemodynamic, and acid-
base homeostasis, CD-fed ASKO mice show renal salt wasting, hyperkalemia, low BP, low bicarbonate, and 
low BW throughout life (Table 1, Supplemental Figures 1 and 2, and Figure 1A), recapitulating human iso-
lated aldosterone deficiency caused mainly by point mutations in the CYP11B2 gene (45, 46). Aldosterone 
deficiency also affects general growth in mice as it does in humans (Figure 1D and Figure 3D). Growth 
retardation in this scenario was not related to salt-wasting-induced extracellular fluid volume depletion but 
to aldosterone-deficiency-induced acidosis (47). Chronic metabolic acidosis impedes growth by inhibiting 
growth hormone (GH) secretion (48) and GH stimulation of  insulin-like growth factor-1 release (49), and 
by reducing the sensitivity of  the bone growth center to GH stimulation (50). A sustained alkaline therapy 
dose-dependently improves growth (51). It can be as effective as a therapy with fludrocortisone, an aldoste-
rone mimetic (47), if  the acid-base balance is restored (52). These clinical findings highlight the key role of  
aldosterone in acid-base balance regulation and the importance of  maintaining an optimal pH for normal 
child growth. A positive energy balance is essential, but not sufficient, for growth success.
Adult, CD-fed ASKO mice at 22°C had greater EE than WT mice. The finding that ASKO mice had 
to spend extra energy to restore acid-base homeostasis by hyperventilation reiterates the importance of  
aldosterone in increasing energetic efficiency by facilitating renal acid excretion. Differences in thermoreg-
ulatory and cardiovascular adjustments due to cold stress may also contribute to the genotype differences in 
EE. Their contributions, however, are likely less than hyperventilation because the EE difference between 
dark and light phase was greater in ASKO mice than in WT mice, and because at each time point in the late 
light phase the EE difference appeared reduced. Also, fasting mice for 12–15 hours at 22°C was sufficient 
to eliminate the genotype difference in EE (Figure 2, C–F). The extra energy costs of  respiration might 
be particularly high during the active phase, accentuating the genotype difference in EE. With increasing 
ventilation, the energy cost of  breathing increases exponentially because in addition to the more forceful 
contraction of  primary respiratory muscles, accessory breathing muscles are recruited to stretch the tho-
racic wall (53, 54). Hyperventilation and increased EE in ASKO mice extended into the early light phase, 
suggesting that to wash out the acid buildup during dark takes time. Changes in EE were tied more closely 
to changes in ventilation in ASKO mice than in WT mice. Thermoneutral housing attenuated hyperventi-
lation in ASKO mice, reducing the genotype difference in EE.
Chronic HFD feeding increased energetic efficiency in ASKO mice. By alleviating the respiratory 
burden and increasing insulin more than in WT mice, HFD feeding gradually increased BW more in 
ASKO than in WT mice. Using fasting-refeeding to minimize influences of  the previous meal and of  dif-
ferences in energy status, we demonstrated that ASKO mice had reduced respiratory and EE responses 
to HFD compared with CD feeding. This reduction was not present in WT mice. Because ASKO mice 
relied more than WT mice on respiration to maintain acid-base balance, the relief  of  this respiratory bur-
den induced by the CD-HFD switch saved more energy in ASKO than in WT mice. This contributed to 
the increased susceptibility of  ASKO mice to HFD-induced obesity. ASKO mice on CD are like chron-
ic obstructive pulmonary disease (COPD) patients, expending large amounts of  energy for ventilation 
to maintain acid-base homeostasis; analogous to the present findings, a HFD nutritional supplement 
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in these patients reportedly alleviates the respiratory burden and minimizes the COPD-related weight 
loss (55–59). Aldosterone deficiency and COPD enhance diet-dependent effects on body acid load and 
thus, on ventilation. They indicate that a reduced body acid load might contribute to the often-described 
beneficial effects of  low-carbohydrate/HFDs (60) and fasting/caloric restriction (61) on cardiopulmo-
nary and vascular health (Figure 8), which has translational significance. Reducing CO2 generation by 
prompting cells to oxidize fat instead of  carbohydrates and by reducing nutrient intake and consequent 
cellular metabolism should alleviate not only the pulmonary but also the cardiovascular burden because 
Figure 7. I.c.v. aldosterone supplementation attenuated hyperinsulinemia and tended to reduce BW gain in 10- 12-week HFD-fed ASKO mice. (A) BW 
gain after 4-week i.c.v. infusion of aCSF or aldosterone (n = 4–7/group, mean ± SEM). (B) Plasma aldosterone levels measured 4 weeks after infusion onset 
(n = 4–7/group, mean ± SEM). (C) Changes in plasma insulin levels 10 days and 15 days after infusion. Blood was collected from the tail at the dark phase 
(n = 4–7/group, mean ± SEM). (D) Daily food intake at 3–4 weeks after infusion (n = 4–7/group, mean ± SEM). (E–G) Changes in daily (E) energy expenditure 
(EE), (F) O2 consumption, and (G) CO2 production measured 3–4 weeks after infusion (n = 4–7/group, mean ± SEM). (H) Western blot analysis of p-HSL, 
HSL, ATGL, and actin in mesenteric fat of HFD-fed WT and ASKO mice after 4-week i.c.v infusion of either aCSF or aldosterone. Results presented as 
relative protein levels of p-HSL and ATGL after normalization to corresponding HSL and actin (n = 4–7/group, mean ± SEM). *P < 0.05, **P < 0.01, ***P < 
0.001; aldosterone-infused ASKO versus aCSF-infused ASKO by Welch’s unpaired t test. aCSF, artificial cerebrospinal fluid.
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it diminishes the central chemoreceptor reflex, which has implications in the progression of  chronic heart 
failure (62). In this reflex, chemoreceptor activation in response to increased arterial pCO2, and indirectly 
to low pH, stimulates the brainstem to enhance breathing and the sympathetic output to the vascular bed 
and heart. Therefore, such dietary intervention may especially benefit hypermetabolic patients such as 
viscerally obese people, who also happen to have an increased central chemoreflex sensitivity (63) and an 
enlarged VAT hampering respiration by impeding the contraction of  the diaphragm.
In addition to the genotype differences in the energy-sparing response to the CD-HFD switch, ASKO 
and WT mice also differed in their hyperinsulinemic response to chronic HFD feeding. ASKO mice on 
HFD developed hyperinsulinemia sooner and more robustly than WT mice (Supplemental Figure 8), with 
insulin reaching nearly 5 times the levels of  WT controls after 8 weeks on HFD, and were not more insulin 
resistant (Figure 6F). As chronic i.c.v. infusion of  aldosterone in ASKO mice reestablished two-thirds of  
control plasma aldosterone levels and attenuated HFD-induced hyperinsulinemia (Figure 7, B and C), 
aldosterone deficiency obviously increases plasma insulin levels with HFD feeding. CD-fed ASKO mice 
also demonstrated a greater insulin response during a hyperglycemic clamp study than controls while being 
Figure 8. Potential beneficial effects of energy intake restriction or low carbohydrate intake (compared with isocaloric high carbohydrate intake) on the 
respiratory and cardiovascular systems. 1. Cells oxidize food-derived nutrients delivered by the arterial blood together with oxygen. Cellular respiration 
generates CO2 and other acidic metabolic waste (lactic acid, ketone bodies). 2. Lungs and kidneys cooperate to eliminate CO2 (lungs) and acids (kidneys). 
3. Respiratory elimination of CO2 is under the control of the breathing center in the brainstem as part of a central chemoreceptor reflex. 4. Activation of 
central chemoreceptors stimulates breathing and enhances sympathetic output to the cardiovascular system, in essence increasing BP. 5. Carbohydrate 
oxidation generates more CO2 than fat (fatty acid) oxidation. Therefore, in conditions with reduced lung function (e.g., chronic obstructive pulmonary dis-
ease patients) and reduced renal acid elimination (e.g., aldosterone deficient mice), and/or hypermetabolism (e.g., obese people), promoting fat oxidation 
(fasting, isocaloric increase in fat intake at the expense of carbohydrates) might improve cardiovascular and pulmonary function.
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similarly insulin sensitive (10). Zucker diabetic fatty rats chronically on ASIs in an oral glucose tolerance 
test did the same (14). These findings suggest that a genetically or pharmacologically reduced aldosterone 
level somehow augments nutrient-dependent insulin release.
Hyperinsulinemia increases metabolic efficiency. Chronic insulin administration via osmotic 
minipumps reduced EE and increased BW in mice (37), and the prevention of  chronic hyperinsulinemia 
in HFD-fed mice by a transgenic approach protected the animals from DIO (38). The elevated EE in 
the latter case was attributed to the WAT gaining BAT-like features, without changes in BAT. Similarly, 
the hyperinsulinemia in HFD-fed ASKO mice reduced thermogenic reprogramming and lipolysis only in 
WAT, but not BAT (Figure 4 and Supplemental Figures 5 and 7). Decreased levels of  UCP1 enhance oxi-
dative phosphorylation and slow down temperature-dependent biochemical reactions, thus minimizing the 
energy loss from energy transformation and futile cycles. Insulin, by limiting gluconeogenesis and lipolysis 
and promoting nutrient storage (64), also reduces the nutrient utilization rates and thus also the respiratory 
workload and EE because less O2 is necessary and less CO2 must be eliminated.
Chronic i.c.v. infusion of  aldosterone attenuated diet-induced hyperinsulinemia. Yet, the reduced 
insulin levels did not accordingly increase EE in HFD-fed ASKO mice (Figure 7, C and E), indicating 
that the presence of  aldosterone in ASKO mice counteracts the influence of  hyperinsulinemia on energy 
efficiency. Because the gas exchange rate of  HFD-fed ASKO mice also remained unchanged following 
aldosterone supplementation (Figure 7, E–G), the aldosterone presence in HFD-fed ASKO mice may 
reduce ventilation-related energy cost and, hence, offset the increase in EE resulting from reduced cir-
culating insulin. Unfortunately, we could not assess whether aldosterone supplementation to HFD-fed 
ASKO mice reactivates lipid catabolism in the VAT because aCSF infusion alone activated lipolysis in 
these mice (Figure 7H). Chronic aCSF infusion may influence VAT lipolysis by altering CSF ion con-
centrations, which affects sympathetic activities (65, 66). ASKO and WT mice presumably have different 
CSF compositions, because aldosterone regulates CSF ion concentrations (66), i.c.v. infusion of  normal 
aCSF may therefore change CSF ionic profiles in ASKO mice. On the other hand, i.c.v. aldosterone 
infusion tended to attenuate HFD-induced BW gain in ASKO mice. This may be related to the parallel 
trend towards a reduction in food intake (Figure 7D), which could be due to central or peripheral effects 
of  aldosterone or to changes in CSF electrolyte content in ASKO mice.
Previous studies exploring aldosterone’s effects on adiposity, often with MR blockers, yielded inconsis-
tent results (67, 68). This is perhaps due to varying antiandrogenic or progesterogenic activity of  the MR 
blockers employed (69, 70), or because they differentially inhibited anabolic actions of  glucocorticoids or 
MR-mediated adipogenesis (71). Moreover, MR blockers might shift energy balance by simply altering 
food intake or physiological activities, as MRs are widely expressed in epithelial tissues and metabolic 
organs. MRs in the hypothalamic paraventricular nucleus, in particular, are under the control of  aldoste-
rone and are involved in regulation of  salt homeostasis and pressor responses to stress (72).
In sum, using the preclinical model of  ASKO mice, we characterize aldosterone as an important hor-
mone increasing energetic efficiency. Aldosterone evolved to conserve salt and fluid and to facilitate efficient 
acidic metabolic waste removal in terrestrial vertebrates. By minimizing acid-base disturbance and respiratory 
burden, aldosterone increases the organism’s resilience to stress and diseases that are characterized by hyper-
metabolism. This may explain why during acidosis in mammals, aldosterone levels are increased (2). Hyper-
aldosteronism in human obesity may result from the increased body acid load due to enhanced cell respiration 
and respiratory workload. The recent concept of  mitigating aldosterone’s toxicity to limit organ failure is sup-
ported by several studies (16, 73), but the physiological importance of  aldosterone in maintaining acid-base 
and electrolyte homeostasis as demonstrated here should not be neglected when considering reducing aldo-
sterone level for treatment. By burdening acid-base balance and causing hyperkalemia, reduced aldosterone 
levels may not only unnecessarily complicate the medical conditions as demonstrated in a recent case report 
(74), but also endanger life particularly in patients with preexisting renal insufficiency or pulmonary diseases. 
Moreover, as the ventilation increase relies on the activation of  the chemoreceptor reflex, which also stimu-
lates sympathetic activity in the cardiovascular system and is involved in chronic heart failure (Figure 8), any 
presumed positive effect of  ASIs on cardiovascular health may be counteracted. Aldosterone deficiency also 
accentuated HFD-induced hyperinsulinemia that promoted visceral fat expansion. Therefore, in subjects who 
prefer HFD, ASIs may increase visceral adiposity, which potentially further aggravates the cardiovascular and 
pulmonary burden in viscerally obese people. Though our findings require validation in human subjects, we 
recommend paying attention to potential negative effects on the cardiovascular and pulmonary system and on 
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BW gain when launching ASI-related clinical studies. Based on our work and published studies (26, 32, 53, 
55, 57, 59, 60, 62, 63), we suggest to focus on strategies to reduce body acid load, such as dietary intervention 
to improve cardiovascular health (Figure 8).
Methods
Animal experiments. WT and ASKO mice (129SvEv background) were maintained at 22°C under a 12-h 
light/dark cycle with free access to food and tap water. The ASKO mouse model, generated in the laborato-
ry of  Olivier Smithies, University of  North Carolina, Chapel Hill, North Carolina, USA, was provided by 
Johannes Loffing, University of  Zurich, Zurich, Switzerland. Unless otherwise indicated, only male mice 
were used and they were sacrificed in the nonfasted state.
Fourteen-week DIO study. Ten-week-old WT and ASKO mice were randomly assigned to either CD 
(Kliba 3436, Provimi Kliba AG) or HFD (D12492, Research Diets) (for diet composition see Supplemental 
Table 1) for 14 weeks. BW was assessed weekly. One HFD-fed ASKO mouse developed a skin infection in 
week 10 of  HFD feeding and was excluded from the experiment since then.
After week 14, individual body composition was analyzed by NMR (EchoMRI-100, EchoMedical Sys-
tems). Data for each mouse represent the average of  2 consecutive measurements. One week later, mice 
were singly housed in metabolic cages (Tecniplast) to monitor daily water and food intake, fecal and uri-
nary production, and to collect urine. The experiment comprised a 3-day adaptation and a 2-day measure-
ment period. Another week later, all CD-fed and some HFD-fed mice were anesthetized (isoflurane, 2.5% 
in O2) and sacrificed in the nonfasted state in the early to mid-light phase. The remaining HFD-fed mice 
were sacrificed after 16 hours of  fasting. Immediately after thoracotomy, blood was collected from the right 
ventricle into EDTA-treated Eppendorf  tubes followed by transcardial PBS perfusion (40 ml) and tissue 
collection for molecular (snap frozen in liquid nitrogen) and histological analysis.
BP measurement. In week 10 of  CD or HFD feeding, systolic, diastolic, and mean BP (SBP, DBP, and 
MAP, respectively) were measured (tail cuff  method, model BP-2000, Visitech Systems) in the light phase 
for 3–5 consecutive days following 5 training days, as previously described (75). The SBP, DBP, and MAP 
of  each mouse were determined as the average of  measurements on days 3–5. Each day, measurement 
comprised 9–15 of  20 automatic inflation/deflation cycles in total. Five to 11 daily measurements were 
discarded as “systolic time-out,” often due to excessive movement of  the mouse. Finally, the results were 
averaged for all mice of  each genotype.
Arterial and venous blood collection for blood gas and lactate analysis. Six- to 9-month-old male and female 
mice maintained on CD at 22°C were restrained using a mouse restrainer during tail artery blood collec-
tion. After immersing the tail in 37°C tap water for 10–15 seconds, the ventral tail artery was nicked with a 
scalpel blade at one-third to one-fifth of  tail length from the anus. About 120 μl arterial blood was collected 
into a heparin-coated vial and immediately analyzed for pH, pO2, and pCO2. Then, 150 μl of  venous blood 
was obtained by puncturing the superficial temporal vein for blood gas and for lactate analysis, the latter by 
a portable lactometer (StatStrip Lactate Xpress, Nova Biomedical). The bicarbonate content of  the blood 
sample was automatically calculated by a blood gas analyzer (model ABL80 FLEX CO-OX, Radiometer) 
from the measured pH and pCO2 (Henderson-Hasselbalch equation).
Whole-body plethysmography. Respiratory parameters (RR, tidal volume, MV, inspiratory and expirato-
ry time) of  conscious, unrestrained mice were obtained during mid to late dark phase using whole-body 
plethysmography (WBP) (FinePointe; Buxco/DSI). WBP measures box flow (ml/min) created by pressure 
changes inside the chamber resulting from mouse breathing. By applying Boyle’s law to box flow, WBP 
derives estimates of  mouse respiratory flow and volume. Mice were placed individually into the WBP 
chamber continuously supplied with room air at a rate of  1 l/min. All mice were habituated to the chamber 
for 40 minutes each day for 2 days prior to the measurements (25 minutes preceded by 15-minute acclima-
tion). Results for ad libitum–fed mice represent the average of  3 consecutive day measurements. Results 
for mice in fasted and refed status were obtained after 12–15 hours of  fasting and 1.5 hours of  refeeding.
Indirect calorimetry and locomotor activity. Singly caged mice fed CD or HFD for different periods were 
placed into the individual metabolic chambers with free access to food and water for 4–6 days: 2 days 
adaptation followed by 2 days for the measurement at 22°C and, in some experiments, another 2 days at 
30°C. O2 consumption, CO2, RER, EE, and locomotor activity were analyzed by a PhenoMaster system 
(TSE Systems). All values were measured every 20 minutes and the average values for mice of  the same 
genotypes at each time point are presented in a trend graph as mean ± SEM. EE, O2 consumption, and CO2 
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production, and locomotor activity in the dark and light phases for both genotypes at 22°C and 30°C were 
determined by averaging the corresponding AUC for mice of  the same genotypes.
Fecal energy content. Feces were collected for 3 days and stored at –20°C. The pooled feces were oven-
dried at 60°C for 30 hours. Dried feces (0.8 g) were used to determine the energy content by bomb calorim-
etry (IKA-Calorimeter C1, IKA-Werke GmbH&Co. KG). Daily fecal energy loss (kJ) was calculated by 
multiplying fecal energy content (kJ/g) with daily fecal weight (g).
Collection of  fecal and cecal samples for SCFA analyses. Fecal pellets (3–6 per mouse) were freshly collected 
into headspace autosampler vials directly from the anus of  mice on 3 different days within 2 weeks in the 
mid-dark phase. The last collection occurred at the time of  sacrifice together with the cecal samples. Each 
sample was immediately weighed and stored at –80°C. The SCFA content of  each sample was assessed 
using a TRACE GC Ultra gas chromatograph with a TriPlus RSH autosampler coupled to an ISQ quadru-
pole mass spectrometer (ThermoFisher Scientific).
Pellets were dissolved in 400 μl phosphate buffer (100 mM, pH 7.4) followed by the addition of  100 μl 
internal standard (IS) solution containing a mixture of  distilled water, 0.5 g/l each of  dissolved acetic acid-
d4, propionic acid-d5, and butyric acid-d7 (Cambridge Isotope Laboratories), and 100 μl of  a 0.5 M H2SO4 
solution. Vials were sealed and thoroughly vortexed until pellets were evenly suspended. The vials were 
directly subjected to headspace gas chromatography-mass spectrometry–based (HS-GC-MS–based) SCFA 
analysis. Identification was initially performed by comparing MS spectra and retention times with those 
of  the external calibrators and against the NIST database. Quantification was performed using peak area 
to IS ratios against an external aqueous calibration (range 0.01–2.5 g/l each) and evaluated using Quan 
Browser in Xcalibur 2.2 with the Genesis algorithm. Retention times and quantifier/qualifier ions for each 
compound were as follows (quantifiers underlined): acetic acid 7.81 min, m/z 60, 45; propionic acid 10.2 
min, m/z 74, 45; butyric acid 13.2 min, m/z 60, 73; acetic acid-d4 7.65 min, m/z 63, 46; propionic acid-d5 
9.93 min, m/z 79, 62; butyric acid-d7 12.82 min, m/z 63, 77. QC samples were analyzed repeatedly over the 
whole batch and were ±20% of  the spiked concentration. Final calculated concentrations were related to 
the applied feces wet weight.
Blood and urine biochemical measurements. Plasma levels of  insulin (Ultra Sensitive ELISA Kit, Crystal 
Chem Inc.), NEFA (Zenbio, Inc.), and aldosterone (EIA-5298, DRG International Inc.) were determined 
using commercial kits according to the manufacturers’ instructions. Plasma steroid hormones were mea-
sured using liquid chromatography-tandem mass spectrometry LC-MS/MS, as previously described (76). 
Plasma glucose, TG, cholesterol and creatinine levels were measured by the Zurich Integrative Rodent 
Physiology (ZIRP) core facility of  the University of  Zurich using standard techniques (UniCel DxC 800 
Synchron Clinical System). Plasma and urinary electrolytes (Na+, K+) were determined using an EFOX 
5053 flame photometer (Eppendorf) and urine creatinine was measured by the Jaffe method (77).
Liver TG content. Liver tissue (100–150 mg) was homogenized with 1 ml of  5% NP-40, followed 
by twice heating to 90°C for 5 minutes and cooling down to room temperature. After centrifugation 
(13,000 g for 2 minutes) to remove insoluble material, the extracted TGs were diluted 10-fold with water 
and the amount was determined with a TG quantification kit (ab65336, Abacam). The concentration is 
expressed as mg/g wet weight.
qRT-PCR. Total RNAs were extracted using the NucleoSpin RNA (Macherey-Nagel AG), followed by 
oligo(dT)-mediated reverse transcription using a RevertAid cDNA Synthesis Kit (ThermoFisher Scientific). 
The resultant cDNA was diluted 5-fold for qRT-PCR analysis with Master I SYBR Green qPCR Master 
Mix. qRT-PCR was performed in duplicate for each sample in a LightCycler 480 Real-Time PCR System 
according to the manufacturer’s instructions (Roche). Relative amounts of  mRNA were determined using 
the comparative Ct method and were normalized to GAPDH mRNA expression for which Ct values were 
not altered by genotypes or diets. The value of  the control group was set to 100. Primer sequences are list-
ed in Supplemental Table 2. The gene expression array was performed using the RT2 Profiler PCR Array 
PAMM-049ZF following the manufacturer’s protocol (Qiagen).
Citrate synthase activity assay. Perirenal fat (60 mg) was ground to a fine powder in a liquid nitrogen–
prechilled mortar and pestle in 300 μl sample buffer containing 100 mM MOPs, 100 mM bicin, and 3 mM 
EDTA, pH 8.2. The tissue homogenate was thawed on ice and sonicated 3 times for 10 seconds each, 
separated by at least 30 seconds, to further disrupt the mitochondrial membranes. After centrifugation 
(12,000 g, 7 minutes, 4°C) of  cell lysates to remove cell debris, the soluble fraction was harvested and its 
protein concentration was determined using the Bradford assay.
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Citrate synthase activity was assayed by measuring the oxaloacetate-dependent production of  CoA-SH 
according to the method of  Srere et al. (78). CoA-SH was made spectrophotometrically quantifiable by 
reacting it with DTNB to form TNB, which exhibits maximal absorbance at 412 nm. Briefly, 10 μl of  sam-
ple containing 4 μg protein was first mixed with 180 μl assay solution containing 110 mM MOPS, 110 mM 
bicin at pH 8, 0.2 mM acetyl-CoA, and 0.1 mM DTNB. The assay was conducted in a 96-well plate and 
was started by adding 4 μl of  10 mM oxaloacetate. The plate was read at 1-minute intervals for 30 minutes 
at 412 nm. The absorbance values were plotted against time and the linear part of  the curve was used to 
determine the enzyme activity. All samples were assayed in quadruplicate. Citrate synthase activities are 
reported as U/g of  protein.
Histology and immunofluorescence. Collected tissue slices roughly 3 mm thick were fixed with 10% forma-
lin in PBS for 24 hours at 4°C and embedded in paraffin blocks. Ten-micrometer sections were deparaffin-
ized and stained with H&E. Images were acquired under a light microscope, and the size of  adipocytes was 
determined using ImageJ software (NIH). For immunofluorescence, antigens of  deparaffinized adipose 
sections were unmasked by pressure cooking with citric acid and trisodium citrate buffer before incubation 
with primary antibody at 4°C overnight, followed by secondary antibody incubation at room temperature 
for 1 hour (for sources and concentrations of  antibodies used see Supplemental Figure 3). Images were 
acquired using a Leica DM 6000 fluorescence microscope.
Immunoblotting. Tissue lysates were prepared by homogenizing samples in 50 mM HEPES, 150 
mM NaCl, 1 mM EGTA, 10% glycerol, 1% Triton X-100, 50 mM NaF, 1.2 mg/ml NEM, 10 mM 
Na-dipyrophosphate, 1 mM DTT, and complete protease inhibitor cocktail and centrifuging (13,000 
g, 20 minutes, 4°C). Protein concentration was measured by the Bradford assay. Protein (40 μg) was 
loaded on SDS-PAGE gels and transferred to a PVDF membrane (Immobilon, Millipore). After block-
ing for 1 hour in 5% BSA or nonfat dry milk diluted in TBS containing 1% Tween 20 (TBST), blots 
were incubated overnight with primary antibody at 4°C. Following 3 washes with TBST, membranes 
were incubated with HRP-conjugated secondary antibody for 1 hour at room temperature (for sources 
and concentrations of  antibodies used, see Supplemental Table 3). Proteins were detected using a 
chemiluminescence kit (GE Healthcare) and autoradiography films. Densitometric quantification was 
performed using ImageJ.
I.c.v. infusion. Ten- to 12-week HFD-fed mice received chronic i.c.v. infusions of  either aCSF (Harvard 
Apparatus) or aldosterone (Sigma-Aldrich, 9477) in aCSF (25 ng/h) for 4 weeks using osmotic minipumps 
(Alzet model 2004). The dose of  aldosterone (25 ng/h) used is supraphysiological and was based on a 
previous study (79).
The filled minipumps were connected to a brain cannula with a polycarbonate catheter (Brain Infu-
sion Kit 2, Alzet) and primed in 37°C sterile 0.9% saline for 60 hours before surgery. Under 2%–3% 
isoflurane anesthesia, mice were fixed with the ear bars on a Model 940 stereotaxic frame (David Kopf  
Instruments), which provides 10-μm resolution linear glass scales. A primed minipump was then posi-
tioned subcutaneously, and the brain cannula was unilaterally implanted into the lateral ventricle with 
the following coordinates: anterior-posterior –0.220, medial-lateral +1.000, dorsal-ventral –3.000. The 
cannula was secured to the skull with liquid cyanoacrylate glue, and the skin was closed with 6-O absorb-
able suture. Standard aseptic surgery, prophylactic antibiotics, and analgesia procedures were applied. For 
all animals, the correct attachment of  the cannula to the skull, and the patency of  the cannula-minipump 
ensemble were confirmed at sacrifice.
Statistics. All data were analyzed using online GraphPad software (http://www.graphpad.com/quickcalcs/
ttest1/?Format=SD) or GraphPad Prism 7 and are presented as dot plots with mean ± SEM unless otherwise 
indicated. Group differences were analyzed by unpaired 2-tailed Welch’s t test or Mann-Whitney U test or 1-way 
ANOVA with Tukey’s post hoc test when more than 2 groups were compared, depending on research hypothe-
sis, and considered significant when P < 0.05.
Study approval. All studies were approved by the Veterinary Office of  the Canton of  Zurich, Switzerland.
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